Why Lenz Therapeutics Stock Plummeted by Almost 20% This Week

Core Insights - Lenz Therapeutics experienced a nearly 20% decline in stock price due to a disappointing earnings report and subsequent price target cuts from major banks [1][4] Financial Performance - For Q4 2025, Lenz reported revenue of just under $1.59 million, a significant increase from $0 in Q4 2024 following FDA approval of its first product, VIZZ [2] - The company's net loss deepened to nearly $35.9 million ($1.16 per share), compared to a loss of $12.7 million in the same quarter the previous year, with analysts expecting revenue of $3.1 million and a non-GAAP net loss of $0.90 per share [3] Market Reactions - Citigroup and Bank of America Securities both reduced their price targets for Lenz, with Citigroup cutting its estimate from $52 to $26 per share and Bank of America lowering it from $35 to $29 per share [4] Company Outlook - Despite the recent setbacks, there is potential for Lenz as its product VIZZ addresses a common vision issue, presbyopia, which could attract a large patient base; the company may need more time to effectively market the product [7] Key Metrics - Lenz Therapeutics has a market capitalization of $280 million, with a current stock price range between $8.39 and $9.25, and a 52-week range from $8.39 to $50.40; the gross margin stands at 96.31% [8]